ストックスクリーナーアプリを入手
7.28
1.22%
-0.09
アフターアワーズ：
7.28
前日終値:
$7.37
開ける：
$7.36
24時間の取引高:
1.27M
Relative Volume:
0.64
時価総額：
$936.94M
収益：
$628.25M
当期純損益:
$-78.55M
株価収益率:
-11.74
EPS:
-0.62
ネットキャッシュフロー:
$-29.73M
1週間 パフォーマンス:
-1.75%
1か月 パフォーマンス:
+10.64%
6か月 パフォーマンス:
-58.94%
1年 パフォーマンス:
-48.00%
1日の値動き範囲:
$7.15
$7.415
1週間の範囲:
$7.15
$7.67
52週間の値動き範囲:
$6.08
$19.11
Neogenomics Inc Stock (NEO) Company Profile
NEO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
7.28 | 953.63M | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
402.82 | 148.60B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.90 | 132.07B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
513.36 | 40.34B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.92 | 30.82B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
140.33 | 23.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-15 | 開始されました | Guggenheim | Neutral |
| 2025-04-30 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-12-10 | 開始されました | Jefferies | Buy |
| 2024-05-01 | 再開されました | Craig Hallum | Buy |
| 2023-12-29 | 繰り返されました | BTIG Research | Buy |
| 2023-08-21 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | アップグレード | BTIG Research | Neutral → Buy |
| 2023-02-24 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-02-01 | アップグレード | Needham | Hold → Buy |
| 2022-08-26 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-08-22 | ダウングレード | Needham | Buy → Hold |
| 2022-06-03 | 開始されました | Piper Sandler | Overweight |
| 2022-03-29 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-29 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 再開されました | Stephens | Overweight |
| 2021-12-16 | 開始されました | Cowen | Outperform |
| 2021-11-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 開始されました | Goldman | Buy |
| 2021-02-25 | 再開されました | Needham | Buy |
| 2021-02-25 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-12-11 | 再開されました | BTIG Research | Buy |
| 2020-10-28 | 繰り返されました | Needham | Buy |
| 2020-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2020-08-28 | 開始されました | Guggenheim | Buy |
| 2020-07-29 | 繰り返されました | Needham | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Buy |
| 2020-04-21 | 再開されました | Stephens | Overweight |
| 2020-03-02 | 再開されました | Craig Hallum | Buy |
| 2020-02-28 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | ダウングレード | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 繰り返されました | Needham | Buy |
| 2019-05-01 | 繰り返されました | Needham | Buy |
| 2019-03-29 | 繰り返されました | Needham | Buy |
| 2019-01-03 | 開始されました | Needham | Buy |
| 2018-10-24 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 開始されました | Leerink Partners | Outperform |
| 2018-05-02 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | ダウングレード | BTIG Research | Buy → Neutral |
| 2017-08-24 | 開始されました | Gabelli & Co | Buy |
| 2016-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Neogenomics Inc (NEO) 最新ニュース
Fort Myers-based NeoGenomics to unveil new cancer diagnostics at ASCO 2025 - Gulfshore Business
NeoGenomics unveils new oncology diagnostics at ASCO 2025 By Investing.com - Investing.com South Africa
Neogenomics director Kelly buys $38,000 in common stock - Investing.com Australia
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025 - BioSpace
NeoGenomics unveils new oncology diagnostics at ASCO 2025 - Investing.com
NeoGenomics Approves Key Proposals at Annual Meeting - TipRanks
D. E. Shaw & Co. Inc. Trims Stock Position in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
BNP Paribas Financial Markets Sells 35,979 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Rating of “Hold” from Analysts - Defense World
NeoGenomics introduces c-MET companion diagnostic for NSCLC - Yahoo Finance
Take Care Before Jumping Onto NeoGenomics, Inc. (NASDAQ:NEO) Even Though It's 25% Cheaper - simplywall.st
NeoGenomics launches rapid c-MET diagnostic test for NSCLC - Investing.com Australia
NeoGenomics launches rapid c-MET diagnostic test for NSCLC By Investing.com - Investing.com South Africa
NeoGenomics drops as sequential revenue decline leads to Q1 miss - MSN
Neogenomics Launches C-Met Cdx Assay To Guide Treatment Decisions For Advanced Non-Small Cell Lung Cancer - marketscreener.com
NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer - Business Wire
Ameriprise Financial Inc. Reduces Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
Envista, NeoGenomics, Acadia Healthcare, Astrana Health, and Hims & Hers Health Stocks Trade Down, What You Need To Know - Yahoo Finance
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market - openPR.com
NeoGenomics to Participate in Upcoming June Investor Conferences - Bluefield Daily Telegraph
Leading Oncology Testing Firm NeoGenomics Announces Key June Investor Conference Schedule - Stock Titan
3 Healthcare Stocks with Mounting Challenges - FinancialContent
Guggenheim Begins Coverage on NeoGenomics (NASDAQ:NEO) - Defense World
NeoGenomics To Present At 39th Annual William Blair Growth Stock Conference - ACCESS Newswire
NeoGenomics opposes US PTAB discretionary denial, citing public health concerns - MLex
Guggenheim Begins Coverage of NeoGenomics (NEO) with Neutral Stance | NEO Stock News - GuruFocus
Guggenheim Initiates Coverage on NeoGenomics With Neutral Rating - marketscreener.com
NeoGenomics (NEO) Initiated with Neutral Rating by Guggenheim Analyst | NEO Stock News - GuruFocus
NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Tower Research Capital LLC TRC - Defense World
NEO Q1 Earnings Call: Sales Growth, Pharma Headwinds, and Pathline Integration Shape Outlook - Yahoo Finance
NeoGenomics (NASDAQ:NEO) Upgraded to Hold at StockNews.com - Defense World
Insider Buying: Stephen Kanovsky Acquires Shares of NeoGenomics Inc (NEO) - GuruFocus
Chief Financial Officer of NeoGenomics Jeffrey Sherman Buys 14% More Shares - Yahoo Finance
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in oncology using the UG 100 sequencing platform - SelectScience
NeoGenomics, Inc. to Host Earnings Call - ACCESS Newswire
Insider Buying: Neil Gunn Acquires Shares of NeoGenomics Inc (NE - GuruFocus
Assessing NeoGenomics: Insights From 9 Financial Analysts - Benzinga
Piper Sandler Lowers Price Target on NeoGenomics (NEO) to $12.00 - GuruFocus
Piper Sandler Lowers Price Target on NeoGenomics (NEO) to $12.00 | NEO Stock News - GuruFocus
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays - Investing.com
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays - MarketBeat
NeoGenomics (NEO) Receives Adjusted Price Target from Piper Sand - GuruFocus
NeoGenomics (NEO) Receives Adjusted Price Target from Piper Sandler | NEO Stock News - GuruFocus
NeoGenomics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo
How to Take Advantage of moves in (NEO) - news.stocktradersdaily.com
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2025 Earnings Call Transcript - MSN
NeoGenomics (NEO) Price Target Lowered by Morgan Stanley | NEO S - GuruFocus
NeoGenomics (NEO) Price Target Lowered by Morgan Stanley | NEO Stock News - GuruFocus
NeoGenomics Repays $201.3 Million Convertible Senior Notes - marketscreener.com
NeoGenomics price target lowered to $10 from $17 at Morgan Stanley - Yahoo Finance
NeoGenomics clears $201.25M convertible debt ahead of maturity By Investing.com - Investing.com India
Neogenomics Inc (NEO) 財務データ
収益
当期純利益
現金流量
EPS
0.78%
1.71%
大文字化:
|
ボリューム (24 時間):